Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
International Biotechnology Trust PLC - London-based investment trust managed by SV Health Managers LLP - Says Pfizer Inc's acquisition of its investee Biohaven Pharmaceutical Holding Co Ltd has boosted net asset value by 3.6%. Pfizer on Tuesday announced the acquisition of Biohaven for $148.50 per share, at a 74% premium to the price of Biohaven before the announcement. IBT on Tuesday owned 182,000 shares in Biohaven, which constituted around 5.2% of its NAV.
Current stock price: 593.00 pence
12-month change: down 14%
Copyright 2022 Alliance News Limited. All Rights Reserved.